Emmaus Life Sciences Presents Positive Transfusion Data from a Post-Hoc Analysis of its Phase 3 Clinical Study of Endari® in Patients With Sickle Cell Disease at the 63rd American Society of Hematology (ASH) Annual Meeting Dec 14, 2021 8:23am EST
Emmaus Life Sciences to Webcast Live at Life Sciences Investor Forum on December 16th Dec 09, 2021 8:00am EST
Emmaus Life Sciences' Data on Endari® Accepted for Poster Presentation at the 63rd American Society of Hematology Annual Meeting & Exhibition Dec 06, 2021 8:23am EST
Emmaus Life Sciences Reports Third Quarter Financial Results and Business Highlights Nov 12, 2021 8:23am EST
Emmaus Life Sciences Announces Partnership with UpScript to Provide Telehealth Solutions to Sickle Cell Disease Patients Nov 11, 2021 8:23am EST
Emmaus Life Sciences Enters into Agreement with Asembia to Provide Expanded Patient Support Services Nov 04, 2021 8:23am EDT
Emmaus Life Sciences Submits Application for U.A.E. Marketing Authorization for Endari® Oct 26, 2021 8:23am EDT
Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine Oct 12, 2021 8:23am EDT
Emmaus Life Sciences Reports Financial Results for the Six Months Ended June 30, 2021 Sep 02, 2021 8:45am EDT
